Dawn Health and Merck have unveiled a next-generation digital ecosystem for growth disorders, created to better support patients with Growth Hormone Deficiency (GHD), along with their caregivers and healthcare professionals (HCPs). This launch represents a major advancement in digital health for GHD, enhancing accessibility, user experience, and clinical support.
Over the past year, the two companies have collaborated to evolve the mobile app and HCP portal at the heart of this ecosystem. Powered by the end-to-end Dawn Platform, the upgraded tools offer a more intuitive and engaging experience. The updated app blends playful, child-friendly design with structured features that guide caregivers, while the newly designed HCP portal improves treatment tracking and delivers timely clinical insights. Enhanced security and localization features also enable a broader, global rollout.
This release lays the groundwork for future capabilities. Coming updates will introduce AI-powered features, including growth predictions, personalized treatment insights, and real-time data capture through connected devices to further support individualized care.
“At Dawn Health, we’re committed to transforming digital health with solutions that make a real difference in patients’ lives. This collaboration with Merck reflects our dedication to creating user-centered products that deliver tangible value to patients, caregivers, and healthcare professionals. Powered by the Dawn Platform, this ecosystem is designed to scale and evolve with the needs of growth disorder care. Working alongside a partner so focused on improving outcomes in growth disorders is a true privilege,” said Alexander Mandix Hansen, CEO of Dawn Health.
This partnership underscores a shared vision: to rethink care through technology and set a new standard in growth disorder management.
